Tildrakizumab and Quality of Life in Moderate-to-Severe Psoriasis in Canada
Observes how tildrakizumab affects daily life in adults with moderate-to-severe psoriasis.
Plain-language title generated from the registry record
Registry title: Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
Key facts
- Where
- Burlington, Hamilton, Kanata, Ottawa, Pickering, and Saskatoon, CanadaSee the 7 sites
Where in Canada
- Benchmark DermatologyBurlington, CanadaTaking people
- Locke DermatologyHamilton, CanadaTaking people
- Panorama Dermatology ClinicKanata, CanadaTaking people
- Factor DermatologyOttawa, CanadaTaking people
- Vital Medical CentreOttawa, CanadaTaking people
- Elevate DermatologyPickering, CanadaTaking people
- Saskatoon Dermatology CentreSaskatoon, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chronicle Academy
- Trial code
- NCT07370766
- Record updated
- 11 September 2026
- Original description
This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale skin types III and above.Read full original descriptionShow less
A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale skin types III and above.
The real-world impact, safety and effectiveness of tildrakizumab on patients with moderate-to-severe plaque psoriasis (PsO) remain largely undocumented in Canada, despite its approval in 2018. Given Canada's diverse population, this study presents an opportunity to evaluate tildrakizumab's quality of life, safety and effectiveness in specific demographic groups, particularly those patients with Fitzpatrick scale skin type III and above.
The findings from this study will help optimize care, address unmet needs, and ensure that treatment outcomes are inclusive and reflective of Canada's diverse population.
Inclusion: Adults aged 18 years or older; Diagnosis of moderate-to-severe chronic plaque-type PsO with Fitzpatrick scale type III or above (BSA >/=3%); Candidate for phototherapy and/or systemic therapy; Planning to initiate tildrakizumab as part of routine clinical care through the ILUMYA SUPPORT® Program for the treatment of plaque PsO but has not yet received their first dose; Decision to treat with tildrakizumab must be made independently of and prior to study recruitment; Must be able to read, understand, and communicate in English; Must be willing to participate in the study and capable to provide informed consent; Able to comply with all study procedures and attend all study visits.
Exclusion: Concurrently taking any oral medication for treatment of PsO (e.g. methotrexate, cyclosporin, acitretin); Concurrent medical condition or significant comorbidities that, in the investigator's opinion, would prevent participation in the study or interfere with study assessments; Prior (within 30 days) or actively participating in other interventional clinical trial(s); Known hypersensitivity to tildrakizumab, its excipients, or components of the container, as outlined in the Product Monograph; Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results; Diagnosis of only palmoplantar psoriasis; Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding; Unable or unwilling to comply with study procedures including completing questionnaire.